Mode
Text Size
Log in / Sign up

Mobile App with Contingency Management Improves Pain Outcomes in Adults with NF1Can a phone app help adults with NF1 manage their chronic pain?

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider iCanCope + contingency management as a preliminary digital auxiliary option for NF1 pain, noting limited safety data.

A randomized clinical trial evaluated 108 adults with Neurofibromatosis Type 1 (NF1) and chronic pain. Participants were assigned to one of three groups: the iCanCope mobile application (iCC-NF), iCanCope plus contingency management (iCC-NF + CM), or treatment as usual (control). The study followed participants for 2 months, though the primary outcome was not specified.

Compared to the control group, the iCC-NF + CM group showed statistically significant improvements across several secondary pain-related outcomes. Effect sizes were moderate to large: pain interference (d = 0.815, p = 0.005), pain self-efficacy (d = 0.718, p = 0.009), pain inflexibility (d = 0.629, p = 0.026), and chronic pain acceptance (d = 0.653, p = 0.036). The study did not report absolute numbers or event rates for these outcomes. No significant differences were found between the iCC-NF + CM and iCC-NF groups.

Safety and tolerability data, including adverse events and discontinuations, were not reported. The study did not specify a primary outcome, and the evidence remains preliminary with a 2-month follow-up. The randomized design suggests possible causality for comparisons with the control group. For clinicians, this provides initial data on a digital auxiliary treatment option for chronic pain in NF1, but the lack of safety information and longer-term outcomes warrants caution.

For adults living with Neurofibromatosis Type 1 (NF1), chronic pain is a common and often debilitating reality. A new study asked if a smartphone could offer some relief. Researchers tested a mobile app called iCanCope, which teaches cognitive behavioral therapy skills for managing pain. One group used the app plus a 'contingency management' system—essentially a structured reward program for engaging with the lessons. Another group just used the app, and a third group continued with their usual care.

After two months, the adults who used the app with the reward system reported meaningful improvements compared to those who stuck with usual care. They felt their pain interfered less with daily life, had more confidence in their ability to manage it, and were more accepting of their pain. The effect sizes, which measure the strength of these improvements, were moderate to large, suggesting the changes were noticeable to the people experiencing them.

The trial involved 108 adults with NF1, which gives us a first look, but it's still a relatively small group. Importantly, the study didn't find a significant difference between the group that used the app with rewards and the group that used the app alone. This means we can't yet say the reward system is the key ingredient. The researchers also didn't report any safety data or what they originally set as their main goal to measure, which are important pieces of the puzzle.

This research points to a promising, accessible tool that could sit alongside other treatments. But it's a preliminary signal. We need larger, longer studies to see if these benefits hold up over time, to understand exactly how the app helps, and to ensure it's safe for everyone.

What this means for you:
A pain management app with rewards showed early promise for adults with NF1, but more research is needed.

Study Details

Study typeRct
EvidenceLevel 2
Follow-up2.0 mo
PublishedApr 2026
View Original Abstract ↓
Neurofibromatosis Type 1 (NF1) is an autosomal dominant genetic disorder that presents with severe chronic pain (CP) in adults. A limited number of NF1 research studies have evaluated behaviorally based interventions to address CP. The current study evaluated the efficacy of cognitive behavior therapy delivered via mobile application. The three-arm (treatment as usual [control], iCanCope only [iCC-NF], iCanCope + contingency management [iCC-NF + CM]) randomized clinical trial of 108 adults with NF1 and CP was completed during a 2-month intervention period. Significant improvements in pain interference (p = 0.005, d = 0.815) occurred in the iCC-NF + CM group when compared to the control group. Outcomes for pain self-efficacy (p = 0.009, d = 0.718), pain inflexibility (p = 0.026, d = 0.629), and chronic pain acceptance (p = 0.036, d = 0.653) significantly improved among the iCC-NF + CM group when compared to the control group. No significant differences were noted between iCC-NF + CM and iCC-NF. The current findings offer preliminary evidence of the added benefit of contingency management to mobile pain applications and provide an auxiliary treatment option for individuals with NF1. Trial Registration: ClinicalTrials.gov identifier: 2000029045.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.